SABCS

Enhertu May Help Preserve Quality of Life in HER2-Positive Breast Cancer

December 19th 2024, 10:00pm

Article

Treatment with Enhertu showed favorable outcomes regarding health-related quality of life in patients with HER2-positive breast cancer, regardless of brain metastases.

Targeting Multiple Pathways Improves Outcomes in Some With Metastatic Breast Cancer

December 19th 2024, 8:00pm

Video

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

Surgical Intervention May Improve Survival in Young Patients with Breast Cancer

December 17th 2024, 10:00pm

Article

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

December 16th 2024, 2:00pm

Article

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer

December 13th 2024, 9:37pm

Article

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

HER3-DXd With or Without Femara Effective for Some With High-Risk Breast Cancer

December 13th 2024, 3:00pm

Article

Patients with high-risk, HR-positive, HER2-negative breast cancer treated with HER3-DXd with or without Femara (letrozole) experienced fewer side effects than with chemotherapy.

Understanding Genetics May Predict Treatment Response in Triple-Negative Breast Cancer

December 13th 2024, 2:00pm

Article

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

Postoperative Radiation Offers Higher Quality of Life, Fewer Side Effects in Some with Breast Cancer

December 12th 2024, 10:00pm

Article

Radiation therapy resulted in improved quality of life and fewer side effects for older patients with stage 1 luminal-like breast cancer than endocrine therapy.

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

December 12th 2024, 8:43pm

Article

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.

Ultra-Sensitive ctDNA Testing Can Detect ctDNA in HR+ Breast Cancer

December 12th 2024, 7:00pm

Article

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.